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PChronic Coronary Disease
latelet Response to Low-Dose Enteric-Coated
spirin in Patients With Stable Cardiovascular Disease
ndrew O. Maree, MSC, MD,* Ronan J. Curtin, MSC, MD,* Michelle Dooley, BSC,*
onan M. Conroy, BA, DSC,† Peter Crean, MD, FRCPI,‡ Dermot Cox, BSC, PHD,*
esmond J. Fitzgerald, MD, FRCPI§
ublin, Ireland
OBJECTIVES We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of
cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase
(COX) inhibition in all individuals.
BACKGROUND Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular
disease; however, there is variability in the way individuals respond. Persistent normal platelet
function despite therapy, referred to as “aspirin resistance,” is associated with an increased risk
of major cardiovascular events.
METHODS We studied 131 stable cardiovascular patients between March and September 2002 who were
taking 75 mg EC aspirin. Serum thromboxane (TX) B2 levels were assayed as a measure of
COX activity. Mean arachidonic acid (AA)-induced platelet aggregation 20% was deemed
evidence of persistent platelet activity and an incomplete aspirin response.
RESULTS Patients of median age 63 years (61% men) were enrolled. Forty-four percent of patients had
elevated serum TX B2 levels (2.2 ng/ml). Arachidonic acid-induced platelet aggregation
occurred more frequently in these patients (21% vs. 3%; p  0.004). In all cases addition of
exogenous aspirin during the assay abolished platelet aggregation. Patient weight and age
were significant independent predictors of an incomplete response to EC aspirin (p  0.025
and p  0.001, respectively). These patients were also more likely to have a history of
myocardial infarction (MI) (p  0.038).
CONCLUSIONS Many patients who are prescribed low-dose EC aspirin for secondary prevention of
cardiovascular events have persistent uninhibited platelet COX activity. Younger and heavier
patients and those with a previous MI are most likely to have an inadequate response to
treatment. (J Am Coll Cardiol 2005;47:1258–63) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.058Cardiology Foundation
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ispirin reduces cardiovascular morbidity and mortality in
atients with pre-existing vascular disease and is therefore
idely prescribed for secondary prevention of cardiovascular
vents (1). Aspirin acts by irreversibly inhibiting platelet
yclooxygenase (COX), the enzyme that catalyzes conver-
ion of arachidonic acid (AA) to thromboxane (TX) A2
Fig. 1) (2). Thromboxane A2, a short-lived platelet agonist,
nhances aggregation in response to most platelet activators
3). Being anucleate, the platelet cannot regenerate COX
nce inhibited, and therefore recovery of TX A2 biosynthe-
is depends on new platelet formation, which occurs at a rate
f 10% daily. Thus, irreversible enzyme deactivation com-
ined with slow recovery of platelet COX explains the
rofound inhibitory effect on platelet TX formation
chieved with low-dose aspirin therapy (4,5).
Substantial inhibition of platelet COX is required to
revent TX formation and subsequent platelet aggregation.
From the Departments of *Clinical Pharmacology and †Epidemiology and Public
ealth, Royal College of Surgeons in Ireland, Dublin, Ireland; and the Departments
f Cardiology, ‡Beaumont Hospital and §St. James’s Hospital, Dublin, Ireland. Drs.
aree, Curtin, Cox, and Fitzgerald contributed equally to the study. The Irish Heart
oundation and the Higher Education Authority of Ireland sponsored this study.t
Manuscript received February 11, 2005; revised manuscript received June 7, 2005,
ccepted June 13, 2005.ndeed, 95% inhibition of enzyme activity is necessary to
uppress aggregation in healthy volunteers (6). Aspirin is the
nly COX inhibitor known to sustain such levels of inhi-
ition with once-daily dosing. This is achieved with 80 to
60 mg of plain (non-coated) aspirin used for secondary
revention of cardiovascular disease (7). Despite the fact
hat this dose range is 2.5- to 10-fold greater than the 30 mg
aily dose reported to fully inactivate platelet COX (5),
esponse to aspirin therapy is variable. Continued platelet
ctivity has been reported in 5% to 40% of patients, a
henomenon referred to as “aspirin resistance” (8,9). One
ecent study associated aspirin resistance, defined as persis-
ent platelet aggregation in vitro, with a three-fold increased
isk of major cardiovascular events (10).
In an earlier crossover study of healthy volunteers, we
ompared different preparations of aspirin at low doses and
ound that enteric-coated (EC) aspirin was less effective
han plain aspirin. This difference was most obvious in
eavier patients (11). On the basis of this finding, we
ypothesized that low-dose EC aspirin preparations, fre-
uently prescribed for secondary prevention of cardiovascu-
ar events, may provide inadequate drug bioavailability and
ncomplete inhibition of platelet COX and thus contribute
o the phenomenon of aspirin resistance.
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atients. The ethics committees of Beaumont and St.
ames’s Hospitals, Dublin, Ireland, approved the study
rotocol, and written informed consent was obtained from
ll patients before enrollment. Men and women age 21 years
nd older were recruited consecutively while attending
ardiology outpatient clinics at one of two tertiary referral
ospitals in Dublin, Ireland, between March and September
002. Patients were identified by medical chart review in the
utpatient clinic. Of the 412 charts reviewed, 208 patients
ad cardiovascular disease, which had been documented by
ardiac catheterization or determined by medical history,
lectrocardiography, and exercise testing, and were taking
spirin daily. Those with a recent history (within 6 weeks) of
yocardial infarction (MI), unstable angina, coronary an-
ioplasty, coronary artery bypass grafting, or major surgical
rocedure were ineligible. Patients with myeloproliferative
isease, personal or family history of bleeding disorders, a
latelet count150,000/l or450,000/l, or hemoglobin
8 g/dl were excluded. Recent ingestion (within 2 weeks)
f non-steroidal anti-inflammatory drugs (NSAIDs), other
OX inhibitors, alternative antiplatelet therapy, or antico-
Abbreviations and Acronyms
AA  arachidonic acid
COX  cyclooxygenase
EC  enteric-coated
MI  myocardial infarction
NSAIDs  non-steroidal anti-inflammatory drugs
TX  thromboxaneh
igure 1. The role of cyclooxygenase-1 in thromboxane (TX) synthesis and
he inhibitory action of aspirin. PGH2  prostaglandin H2.gulants were also criteria for exclusion. Of these 208
atients, 158 were taking a 75-mg EC aspirin preparation
76%). These patients were then requested to participate in
he study and 131 (83%) agreed to do so. The main reason
or non-participation was an unwillingness to attend the
linic for further unscheduled visits.
tudy design and main outcome measures. To optimize
ompliance, all patients were informed that the purpose of
he study was to assess their response to aspirin. Demo-
raphic data and concomitant medication were recorded by
irect interview and from the medical chart. Follow-on
ppointments were scheduled for assessment of platelet
esponse to aspirin. Patients were re-contacted several days
n advance and the day before to confirm the appointment
nd remind them to take their aspirin daily, including the
orning of the test.
Serum TX B2, the stable metabolite of TX A2, was
ssayed as a measure of COX activity in blood (largely in
latelets) (12). To further determine the presence of unin-
ibited platelet COX, the amount of TX B2 produced when
A was added to platelet-rich plasma, referred to as
platelet TX,” was determined in a subgroup. Because COX
s a catalytic enzyme, if incomplete aspirin inhibition of
latelet COX exists, addition of a high concentration of its
ubstrate, AA, results in production of large amounts of its
nd product, TX, and thus provides a highly sensitive assay
f aspirin response (Fig. 1).
Platelet aggregation to AA (1.6 mmol/l) was measured by
ight transmission in platelet-rich plasma as previously
escribed (8). Arachidonic acid-induced platelet aggrega-
ion 20% was deemed evidence of continued platelet
ctivity and potential for thrombus formation (10). When
ignificant platelet aggregation to AA was detected, the
ssay was repeated following in vitro addition of aspirin (2.5
o 50 mol/l) (13).
tatistical analysis. Results are reported as median and
5th to 75th percentile range for continuous variables and
ercentages for discrete variables. The Student t test was
sed to compare continuous data and the Fisher exact test
or discrete data. Non-parametric data were analyzed by the
ann-Whitney test and data correlation was determined
sing Spearman’s rank-correlation coefficient. A two-tailed
value of 0.05 was considered statistically significant.
ultiple-variable analysis was performed by analysis of
ariance (ANOVA). Predictors of treatment failure and
ailure to inhibit serum TX B2 generation were examined
sing logistic regression, and predicted probabilities of
on-inhibition were generated.
ESULTS
atient characteristics. A total of 131 patients with me-
ian age 63 years (55 and 71.5, 25th and 75th centiles,
espectively) were enrolled consecutively in the study. Sixty-
ne percent (n  80) were men, 39 (n  51) percent had a
istory of MI, 44% (n  58) had previously undergone
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Aspirin and Coronary Artery Disease October 4, 2005:1258–63oronary artery revascularization, 52% (n  68) had a
istory of hypertension, 10% (n 13) were diabetic, 18% (n
24) were current smokers, and 66% (n  86) were taking
tatin therapy (Table 1).
latelet and serum TX B2. Serum TX B2 was markedly
uppressed in most patients. A plot of platelet TX B2 versus
erum TX B2 revealed a sigmoid relationship (n 45, R
2
.67). Incomplete COX inhibition, reflected by platelet TX
ormation, was detected when serum TX B2 values exceeded
.2 ng/ml (Fig. 2). This reflects the concentration of serum
hromboxane that is associated with 50% of the maximum
latelet thromboxane levels in a log scale and is equivalent to
n EC50 value. Thus, levels of serum TX B2 2.2 ng/ml
ere deemed evidence of incomplete aspirin response.
latelet TX generation also correlated closely with AA-
nduced platelet aggregation (n  45, R2  0.9) (Fig. 3).
Forty-four percent of patients had a serum TX B2 level
2.2 ng/ml indicating suboptimal inhibition of platelet
OX and an incomplete aspirin response. Seventeen per-
ent of the population had values exceeding 10 ng/ml.
atients with an incomplete aspirin response were more
ikely to demonstrate platelet aggregation to AA (21% vs.
igure 2. A sigmoid relationship between serum thromboxane (TX) (ng/ml) on
he y-axis and platelet TX (ng/ml) (TX generated when exogenous arachidonic
2
Table 1. Comparative Analysis of Patients Stra
All Patients
(n  131)
Weight (kg) 77.0 ( 69.6, 86.0)
Age (yrs) 63.0 ( 55.0, 71.5)
Body mass index (kg/m2) 27.6 ( 25.4, 30.1)
Gender (male) 61
Smoking 18
Diabetes 10
Statin 66.2
Beta-blocker 63.1
ACE inhibitor 27.6
Previous revascularization 44
Previous myocardial infarction 39
ACE  angiotensin-converting enzyme; TX  thromboxancid is added to platelets) on the x-axis is evident (n 45, R  0.67). The point
f inflection of the graph occurs at a serum TX level of 2.2 ng/ml.
T
a%; p  0.004). Figure 4 shows the relationship between
erum TX and AA-induced aggregation. At TX levels of
pproximately 2 ng/ml, the population divides into two
roups: one group maintains a low percentage of aggrega-
ion, even with TX levels as high as 100 ng/ml; the second
roup shows maximal aggregation at TX levels as low as 3
g/ml. However, in all cases when platelet aggregation
ccurred it was abolished by addition of aspirin in vitro.
Patient weight, age, and body mass index were significant
redictors of incomplete suppression of serum TX B2
ormation by aspirin. Weight and age remained indepen-
ent determinants of this incomplete treatment response on
ultiple regression analysis (p  0.025 and 0.0086, respec-
ively) (Table 1). Patients who showed an inadequate
esponse to aspirin were heavier, younger (Fig. 5), and more
ikely to have had a previous MI (p  0.038).
ISCUSSION
any cardiovascular patients who take aspirin for secondary
revention will have further vascular events. Indeed, treat-
igure 3. Platelet thromboxane generation (ng/ml) on the x-axis correlates
ith arachidonic acid-induced platelet aggregation (%) on the y-axis (n 
5, R2  0.9). Both variables depend on cyclooxygenase (COX) activity.
by Serum Thromboxane Value
X <2.2 ng/ml
(n  74)
TX >2.2 ng/ml
(n  57) p Value
6.0 ( 64.5, 80.8) 83 ( 75.0, 89.0) 0.025
7.0 ( 57.0, 73.0) 59.0 ( 54.0, 64.0) 0.0086
7.1 ( 24.7, 29.4) 28.4 ( 26.0, 31.0) 0.04
54.1 70.2 0.11
18.9 17.9 0.92
10.8 8.9 0.85
66.2 66.1 0.99
67.6 57.1 0.3
25.4 30.8 0.6
39.2 50.9 0.19
31.1 49.1 0.038tified
T
7
6
2wo distinct populations are evident reflecting absence and presence of
ctive platelet COX.
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October 4, 2005:1258–63 Aspirin and Coronary Artery Diseaseent with aspirin before presentation with an acute coro-
ary syndrome indicates poor prognosis (14). However, this
ay reflect complex pathology rather than resistance to
herapy. Failure to respond fully to aspirin, referred to as
spirin resistance, has been detected using a variety of
latelet function assays. These include platelet aggregation
o AA, thrombus formation on collagen membranes, and
X generation in vivo (10,13,15). Each assay, however,
easures a distinct aspect of platelet function, which may
xplain variation in the reported prevalence of aspirin
esistance.
To address what constitutes aspirin “resistance” or “non-
esponse” it is important to define what response is expected
nd with what assay. We know that in vivo, erythrocytes
nd leukocytes modulate platelet reactivity (16), whereas
ollagen, ADP, TX A2, thrombin, epinephrine, serotonin,
nd shear stress act synergistically on the platelet. Ex-vivo
eplication of this environment is impractical; however,
ssays of serum TX B2 generation and AA-induced platelet
ggregation depend on COX-1 function and thus reflect
spirin’s pharmacologic effect on platelets (17).
Reasons for failure to respond to aspirin may be pharma-
okinetic (failure to achieve an adequate level of drug) or
harmacodynamic (failure to inhibit platelet function).
tudies to date have largely overlooked this distinction
ecause it is assumed that all preparations deliver an
dequate aspirin dose. Interindividual pharmacodynamic
ariability occurs with most drugs, and aspirin is no differ-
nt; thus, aspirin resistance assays may reflect, at least in
art, pharmacodynamic heterogeneity. In addition, when
ontemplating causes of resistance to any drug, poor patient
ompliance, inadequate dosing and drug interaction must
lso be considered at the outset. We went to considerable
engths to confirm patient compliance and prevent drug
nteraction.
Dose-finding studies on which current regimens are
ased used plain aspirin, which differs significantly in its
igure 4. The relationship between serum thromboxane (TX) and arachi-
onic acid-induced platelet aggregation (AA Agg). At thromboxane levels
bove 2 ng/ml the population divides into two groups, one with full
nhibition and the other with no inhibition of arachidonic acid-induced
latelet aggregation.harmacokinetic profile from EC preparations. Seminal
p
0tudies demonstrated that TX generation is highly suscep-
ible to aspirin inhibition and that profound cumulative
nhibition of platelet TX production occurred with chronic
dministration of low-dose plain aspirin (5,18). With such
spirin preparations, peak plasma levels occur 30 to 40 min
fter ingestion and platelet inhibition is apparent after 1 h.
n contrast, it takes 3 to 4 h to achieve peak plasma levels
ith EC aspirin (19). In a healthy volunteer study, we
etected lower efficacy with EC preparations compared with
lain aspirin (11). This finding is of increasing importance
ecause many patients who take aspirin as antiplatelet
herapy for secondary prevention of cardiovascular events
ow receive low-dose EC preparations (76% of our popu-
ation).
Aspirin is rapidly inactivated by enzymatic and non-
nzymatic hydrolysis to salicylate, thus assays of plasma
spirin concentration provide an unreliable index of bio-
vailability. Therefore we used functional assays of aspirin’s
ffect and concentrated on inhibition of platelet COX, its
arget enzyme (19). Aspirin acetylates a serine residue in the
ubstrate pocket of COX in an irreversible reaction that
nactivates the enzyme. We assayed serum TX B2, a
easure of the enzyme’s capacity to generate the parent
ompound TX A2 from endogenous AA stored in the
latelet membrane (Fig. 1). Even a trivial level of enzyme
ctivity can generate sufficient amounts of TX to support
latelet activity. Thus, at least 95% suppression of serum TX
2 is required to achieve an optimal antiplatelet effect (6).
In a subset of patients we also measured the ability of
latelets to metabolize exogenous AA and form TX (platelet
X). This index of platelet COX activity correlated with
latelet aggregation. Comparison of serum and platelet TX
2 levels demonstrated that when serum levels exceeded 2.2
g/ml (equivalent to the IC50 value), platelets continued to
enerate TX from AA, indicating the presence of uninhib-
ted enzyme (Fig. 2). This value is also close to mean serum
hromboxane  1 SD (1.5  1.1 ng/ml, n  25) for 75 mg
spirin in healthy volunteers (unpublished data). Consistent
ith this, platelets from these patients were more likely to
igure 5. Probability of an incomplete response to aspirin (serum throm-
oxane 2.2 ng/ml) on the y-axis is related to patient weight on the x-axis
nd stratified by patient age. Weight and age are significant independent
redictors of aspirin response on multivariate analysis (p  0.025 and
.0086, respectively).
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Aspirin and Coronary Artery Disease October 4, 2005:1258–63xhibit aggregation to AA. In a previous study among
ealthy volunteers taking 75 mg plain aspirin, mean serum
X B2  1 SD was 1.5  1.1 ng/ml, n  25. In the same
tudy, serum TX B2 values seen in untreated subjects were
45  111 ng/ml ( SD), n  74 (unpublished data).
hus, our results indicate that profound inhibition (99%) of
erum TX is necessary to achieve optimal platelet suppres-
ion. Even a more generous target serum TX level of 3.2
g/ml, which corresponds to maximum levels of platelet TX
eneration in our population, is equivalent to 98.7% inhi-
ition of serum TX levels (Fig. 2).
Of 131 patients taking 75 mg EC aspirin daily, 58 (44%)
ailed to attain optimal inhibition of serum TX (2.2
g/ml) (Table 1). Heavier and younger patients were less
ikely to respond to aspirin. For example, if a 50-year-old
atient weighed 90 kg (198 lb), the likelihood of an
nadequate treatment response was 70% (Fig. 4). In every
ase where platelet aggregation to AA was detected, addi-
ion of aspirin overcame the platelet response. These results
uggest that the dose of aspirin delivered by 75 mg EC
reparations is not sufficient to prevent platelet activity in
any cases and that larger subjects are most at risk of an
nadequate response to treatment.
Bioavailability of plain aspirin given orally is approxi-
ately 50% (20). Deactivation of aspirin by hydrolysis to
alicylate may occur at a number of sites, including the gut,
iver, and blood. Aspirin (pKa  3.5) is highly protonated
nd thus rapidly absorbed from the stomach where the pH
s low and hydrolysis is minimal. In contrast, EC prepara-
ions release aspirin into the upper small intestine, where
he pH of 6.5 exceeds the drug’s pKa and thus aspirin is less
rotonated and absorbable. Here slower absorption and a
ore alkaline environment may facilitate hydrolysis to
alicylic acid, and thus bioavailability of aspirin from these
reparations may be lower (19,21). Plain aspirin, at doses as
ow as 40 mg, fully inhibits platelet aggregation in healthy
olunteers. Low doses of EC aspirin may be less bioavailable
nd thus prove insufficient in heavier patients with a large
olume of distribution (22).
The relationship between lower patient age and an
ncomplete response to aspirin is more difficult to explain;
owever, consistent with our findings, particular benefit of
spirin therapy to older stable cardiovascular patients has
reviously been described (23). Age-related changes in drug
ensitivity are increasingly appreciated and both pharmaco-
inetic and pharmacodynamic factors appear to contribute.
he COX gene is polymorphic and variants have been
escribed, which modify response to aspirin (24). Although
ddition of aspirin overcame continued platelet aggregation
hen it occurred in our population, genetic variation in
OX may alter aspirin sensitivity. Heritable factors pre-
ominate in younger patients; thus, genetic factors may
ontribute to the relationship with age. Indeed, family
istory is an independent risk factor for MI, and age of
nset can be related to strength of association (25). The
nability of aspirin to inhibit TX generation in youngeratients therefore may represent evidence of pharmacody-
amic resistance.
Patients who demonstrated suboptimal COX inhibition
ere more likely to have had a previous MI. An association
etween previous MI and increased cardiovascular risk is
ell established (26). One possible explanation for our
ndings is that patients with previous MI may have a more
ggressive disease process and may therefore be inherently
ess sensitive to aspirin. Our finding may represent func-
ional evidence of an incomplete aspirin response. Coinci-
ental administration of NSAIDs such as ibuprofen with
spirin may reduce its efficacy. Ibuprofen occupies the active
ite of COX and can prevent enzyme acetylation by aspirin;
owever, we excluded all patients taking NSAIDs (27).
The Antithrombotic Trialists’ Collaborative meta-
nalysis of 287 antiplatelet trials and 137,000 subjects
eported that 75 to 150 mg of aspirin daily is effective
econdary prevention in patients with cardiovascular disease
7). Although their findings may appear to conflict with
urs, many of the trials used plain rather than coated aspirin
reparations, and, in fact, relatively few patients were taking
he 75 mg aspirin dose. In a healthy volunteer study in
hich five different preparations containing low-dose aspi-
in were evaluated, we found that all volunteers receiving
oluble aspirin had 95% inhibition of serum TX, whereas
etween 5% and 25% of volunteers taking EC aspirin
depending on brand) failed to achieve this (11). Consistent
ith our findings, a recent meta-analysis suggests that
spirin dose upon hospital discharge influences the clinical
ourse after admission with unstable angina or acute MI
28).
onclusions. Our results indicate that inhibition of plate-
et function with 75 mg EC aspirin daily may be incomplete
n many patients with cardiovascular disease. Heavier and
ounger patients and those with a history of MI are most
ikely to demonstrate an inadequate treatment response.
cknowledgment
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